HLB Panagene（A046210）株式概要HLB PANAGENE Co, LTD.は、韓国で分子診断分野の製品を開発している。 詳細A046210 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6報酬過去 1 年間で収益は9.8%増加しましたリスク分析意味のある時価総額がありません ( ₩65B )すべてのリスクチェックを見るA046210 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW502,832 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG502,832 investors already sharing narrativesYour Fair Value₩Current Price₩1.43k38.2% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-7b15b2016201920222025202620282031Revenue ₩14.6bEarnings ₩2.7bAdvancedSet Fair ValueView all narrativesHLB Panagene Co., Ltd. 競合他社Optipharm.CO.LTDSymbol: KOSDAQ:A153710Market cap: ₩67.5bKoBioLabsSymbol: KOSDAQ:A348150Market cap: ₩62.3bPanGen BiotechSymbol: KOSDAQ:A222110Market cap: ₩61.2bABIONSymbol: KOSDAQ:A203400Market cap: ₩61.5b価格と性能株価の高値、安値、推移の概要HLB Panagene過去の株価現在の株価₩1,429.0052週高値₩2,940.0052週安値₩1,242.00ベータ-0.241ヶ月の変化4.08%3ヶ月変化-40.58%1年変化-28.19%3年間の変化-74.21%5年間の変化-76.38%IPOからの変化-85.67%最新ニュースNew Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩89.5b market cap, or US$60.7m).New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩104.4b market cap, or US$70.9m).Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩2,030, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 49% over the past three years.お知らせ • Feb 26HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 54, techno 10-ro, yuseong-gu, daejeon South KoreaValuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩2,160, the stock trades at a trailing P/E ratio of 58.4x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 45% over the past three years.分析記事 • Jan 27Does HLB PANAGENE (KOSDAQ:046210) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...最新情報をもっと見るRecent updatesNew Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩89.5b market cap, or US$60.7m).New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩104.4b market cap, or US$70.9m).Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩2,030, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 49% over the past three years.お知らせ • Feb 26HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 54, techno 10-ro, yuseong-gu, daejeon South KoreaValuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩2,160, the stock trades at a trailing P/E ratio of 58.4x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 45% over the past three years.分析記事 • Jan 27Does HLB PANAGENE (KOSDAQ:046210) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Board Change • Dec 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩77.8b market cap, or US$56.1m).Board Change • Aug 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Feb 22HLB PANAGENE Co., LTD., Annual General Meeting, Mar 24, 2025HLB PANAGENE Co., LTD., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 54, techno 10-ro, yuseong-gu, daejeon South Koreaお知らせ • Oct 29+ 1 more updateHLB PANAGENE Co., LTD. (KOSDAQ:A046210) agreed to acquire 9.9% stake in GenoFocus, Inc. (KOSDAQ:A187420) for KRW 8 billion.HLB PANAGENE Co., LTD. (KOSDAQ:A046210) agreed to acquire 9.9% stake in GenoFocus, Inc. (KOSDAQ:A187420) for KRW 8 billion on October 28, 2024. A cash consideration of KRW 7.99 billion will be paid by HLB PANAGENE Co., LTD. The expected completion of the transaction is December 12, 2024.New Risk • Oct 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.4b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (2.9% increase in shares outstanding). Market cap is less than US$100m (₩130.4b market cap, or US$98.7m).New Risk • Sep 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.9% increase in shares outstanding).New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding).お知らせ • May 16HLB PANAGENE Co., LTD. announced that it has received KRW 8.92258042 billion in fundingOn May 14, 2024, HLB PANAGENE Co., LTD. closed the transaction.お知らせ • Jan 25HLB PANAGENE Co., LTD. announced that it has received KRW 2 billion in funding from Gencurix Inc.On January 24, 2024, HLB PANAGENE Co., LTD. closed the transaction.お知らせ • Jan 18HLB PANAGENE Co., LTD. announced that it expects to receive KRW 2 billion in funding from Gencurix Inc.HLB PANAGENE Co., LTD. announced a private placement to issue Series 7 Bearer-Type Unsecured Private Placement Convertible Bonds for the gross proceeds of up to KRW 2,000,000,000 on January 17, 2024. The transaction will include participation from a new investor, Gencurix Inc. The bonds will be 100% convertible into 500,125 shares at a conversion price of KRW 3,999 in a period starting from January 24, 2025 and ending on December 24, 2026. The maturity date of the bonds is January 24, 2027. The transaction is expected to close on January 24, 2024. The transaction has been approved by the board of directors of the company.New Risk • Aug 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding).お知らせ • Jun 22+ 1 more updatePanagene Inc. announced that it expects to receive KRW 29.999994061 billion in funding from HLB Co., Ltd., HLB Investment Co., Ltd., HLB bioStep Co.,Ltd., HLB innoVation Co.,Ltd., HLB Therapeutics Co.,Ltd.Panagene Inc. announced a private placement of 8,867,867 commons shares at an issue price of KRW 3,383 for the gross proceeds of KRW 29,999,994,061 on June 21, 2023. The company will issue share through 3rd party allocation increase. The transaction will include participation from new investors HLB Co., Ltd. for 3,842,743 shares, HLB Investment Co., Ltd. for 591,191 shares, HLB bioStep Co.,Ltd. for 3,251,551 shares, HLB innoVation Co.,Ltd. for 591,191 shares, and HLB Therapeutics Co.,Ltd. 591,191 shares. The expected closing date of the transaction is August 3, 2023. The transaction has been approved by board of directors of the company. The shares are subject to mandatory hold period of one year.New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Is New 90 Day High Low • Jan 14New 90-day high: ₩5,180The company is up 7.0% from its price of ₩4,840 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 26% over the same period.Is New 90 Day High Low • Dec 01New 90-day low: ₩4,105The company is down 14% from its price of ₩4,750 on 02 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.Is New 90 Day High Low • Oct 23New 90-day low: ₩4,380The company is down 9.0% from its price of ₩4,795 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period.株主還元A046210KR BiotechsKR 市場7D-6.2%-2.7%-9.7%1Y-28.2%2.4%131.3%株主還元を見る業界別リターン: A046210過去 1 年間で2.4 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A046210は、過去 1 年間で131.3 % のリターンを上げたKR市場を下回りました。価格変動Is A046210's price volatile compared to industry and market?A046210 volatilityA046210 Average Weekly Movement7.6%Biotechs Industry Average Movement11.0%Market Average Movement9.3%10% most volatile stocks in KR Market16.7%10% least volatile stocks in KR Market4.9%安定した株価: A046210 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A046210の 週次ボラティリティ ( 8% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト197682Sung-Ki Kimwww.hlbpanagene.comHLB PANAGENE Co., LTD.は韓国で分子診断分野の製品を開発している。同社の製品には、肺がん、大腸がん用のリキッドバイオプシー製品、肺がん、甲状腺がん、膵臓がん、大腸がん、膠芽腫、骨髄増殖性新生物、慢性骨髄性白血病、中枢神経系、骨髄線維症、真性多血症用の組織生検製品などがある。また、子宮頸がん、性感染症、極端な薬剤耐性疾患向けの製品、ペプチド核酸製品も提供している。以前はパナジーン社として知られていたが、2023年8月にHLBパナジーン株式会社に社名変更した。HLB PANAGENE Co., LTD.は1976年に設立され、韓国の大田に本社を置いている。もっと見るHLB Panagene Co., Ltd. 基礎のまとめHLB Panagene の収益と売上を時価総額と比較するとどうか。A046210 基礎統計学時価総額₩65.06b収益（TTM）-₩3.62b売上高(TTM)₩14.64b4.4xP/Sレシオ-18.0xPER（株価収益率A046210 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A046210 損益計算書（TTM）収益₩14.64b売上原価₩5.71b売上総利益₩8.93bその他の費用₩12.55b収益-₩3.62b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-79.44グロス・マージン61.01%純利益率-24.70%有利子負債／自己資本比率8.4%A046210 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/08 18:04終値2026/07/08 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋HLB Panagene Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩89.5b market cap, or US$60.7m).
New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩104.4b market cap, or US$70.9m).
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩2,030, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 49% over the past three years.
お知らせ • Feb 26HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 54, techno 10-ro, yuseong-gu, daejeon South Korea
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩2,160, the stock trades at a trailing P/E ratio of 58.4x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 45% over the past three years.
分析記事 • Jan 27Does HLB PANAGENE (KOSDAQ:046210) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
New Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩89.5b market cap, or US$60.7m).
New Risk • Apr 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩104.4b market cap, or US$70.9m).
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩2,030, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 49% over the past three years.
お知らせ • Feb 26HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026HLB Panagene Co., Ltd., Annual General Meeting, Mar 25, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 54, techno 10-ro, yuseong-gu, daejeon South Korea
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩2,160, the stock trades at a trailing P/E ratio of 58.4x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total loss to shareholders of 45% over the past three years.
分析記事 • Jan 27Does HLB PANAGENE (KOSDAQ:046210) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Board Change • Dec 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • Aug 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2013. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Market cap is less than US$100m (₩77.8b market cap, or US$56.1m).
Board Change • Aug 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Feb 22HLB PANAGENE Co., LTD., Annual General Meeting, Mar 24, 2025HLB PANAGENE Co., LTD., Annual General Meeting, Mar 24, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 54, techno 10-ro, yuseong-gu, daejeon South Korea
お知らせ • Oct 29+ 1 more updateHLB PANAGENE Co., LTD. (KOSDAQ:A046210) agreed to acquire 9.9% stake in GenoFocus, Inc. (KOSDAQ:A187420) for KRW 8 billion.HLB PANAGENE Co., LTD. (KOSDAQ:A046210) agreed to acquire 9.9% stake in GenoFocus, Inc. (KOSDAQ:A187420) for KRW 8 billion on October 28, 2024. A cash consideration of KRW 7.99 billion will be paid by HLB PANAGENE Co., LTD. The expected completion of the transaction is December 12, 2024.
New Risk • Oct 02New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.4b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (2.9% increase in shares outstanding). Market cap is less than US$100m (₩130.4b market cap, or US$98.7m).
New Risk • Sep 18New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (2.9% increase in shares outstanding).
New Risk • Jul 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding).
お知らせ • May 16HLB PANAGENE Co., LTD. announced that it has received KRW 8.92258042 billion in fundingOn May 14, 2024, HLB PANAGENE Co., LTD. closed the transaction.
お知らせ • Jan 25HLB PANAGENE Co., LTD. announced that it has received KRW 2 billion in funding from Gencurix Inc.On January 24, 2024, HLB PANAGENE Co., LTD. closed the transaction.
お知らせ • Jan 18HLB PANAGENE Co., LTD. announced that it expects to receive KRW 2 billion in funding from Gencurix Inc.HLB PANAGENE Co., LTD. announced a private placement to issue Series 7 Bearer-Type Unsecured Private Placement Convertible Bonds for the gross proceeds of up to KRW 2,000,000,000 on January 17, 2024. The transaction will include participation from a new investor, Gencurix Inc. The bonds will be 100% convertible into 500,125 shares at a conversion price of KRW 3,999 in a period starting from January 24, 2025 and ending on December 24, 2026. The maturity date of the bonds is January 24, 2027. The transaction is expected to close on January 24, 2024. The transaction has been approved by the board of directors of the company.
New Risk • Aug 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 28% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Shareholders have been diluted in the past year (28% increase in shares outstanding).
お知らせ • Jun 22+ 1 more updatePanagene Inc. announced that it expects to receive KRW 29.999994061 billion in funding from HLB Co., Ltd., HLB Investment Co., Ltd., HLB bioStep Co.,Ltd., HLB innoVation Co.,Ltd., HLB Therapeutics Co.,Ltd.Panagene Inc. announced a private placement of 8,867,867 commons shares at an issue price of KRW 3,383 for the gross proceeds of KRW 29,999,994,061 on June 21, 2023. The company will issue share through 3rd party allocation increase. The transaction will include participation from new investors HLB Co., Ltd. for 3,842,743 shares, HLB Investment Co., Ltd. for 591,191 shares, HLB bioStep Co.,Ltd. for 3,251,551 shares, HLB innoVation Co.,Ltd. for 591,191 shares, and HLB Therapeutics Co.,Ltd. 591,191 shares. The expected closing date of the transaction is August 3, 2023. The transaction has been approved by board of directors of the company. The shares are subject to mandatory hold period of one year.
New Risk • Jun 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported September 2013 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (10% average weekly change).
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Is New 90 Day High Low • Jan 14New 90-day high: ₩5,180The company is up 7.0% from its price of ₩4,840 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 26% over the same period.
Is New 90 Day High Low • Dec 01New 90-day low: ₩4,105The company is down 14% from its price of ₩4,750 on 02 September 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period.
Is New 90 Day High Low • Oct 23New 90-day low: ₩4,380The company is down 9.0% from its price of ₩4,795 on 24 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 11% over the same period.
